Lucemyra is the brand name for lofexidine. Its approved use is narrow, and reading it closely saves a lot of confusion later. The label says it is indicated for the mitigation of opioid withdrawal symptoms, to help adults stop opioids abruptly [1].
Read that again for what it does not say. It does not say treatment of opioid use disorder. It does not say cure, and it does not say prevention. The label is just as direct on the point: the medication may mitigate, but not completely prevent, the symptoms of opioid withdrawal [1].
This page reports what the prescribing information states, and what federal sources say around it. Our hub on medication-assisted treatment covers the wider field.
What the approved use actually covers
Three words in the indication do the work: mitigation, symptoms, and adults [1].
Mitigation means reducing, not removing. Symptoms means the experience of withdrawal, not the underlying disorder. Adults means adults; the label does not extend the use to children.
There is a fourth idea in the same sentence. The phrase is “to facilitate abrupt opioid discontinuation” [1]. This is a medication designed for the situation where someone stops, rather than one designed to keep someone on a stable medication for months or years. Our page on withdrawal symptoms describes what that week involves.
This page carries no dosage, no tablet count, no interval and no treatment length, although the label states all of them [1]. Those belong to the prescriber who is watching the person in front of them. A number lifted from a label and applied at home is how a supervised medication turns into a hazard.
How lofexidine works, and why it is not an opioid
Lofexidine is a central alpha-2 adrenergic agonist [1]. It binds to receptors on adrenergic neurons, which reduces the release of norepinephrine and lowers sympathetic tone [1].
In plainer terms: much of what opioid withdrawal feels like is the body’s alarm system running hot. Sweating, racing pulse, gooseflesh, restlessness, cramping. Lofexidine turns the volume down on that system.
What it does not do is act at the opioid receptor. That matters in both directions. It is not an opioid, so it does not produce opioid effects and it is not a substitute for the drug someone has stopped. It also means it cannot reverse withdrawal the way an opioid medication can; it can only soften it.
Federal treatment guidance describes the same reasoning for clonidine, an older medication in the same family, noting that because clonidine does not interact with the mu-opioid receptor, withdrawal management with it happens without opioids [3]. That is the category lofexidine belongs to.
What the label lists as risks
The prescribing information lists no contraindications at all, and then lists five warnings [1]. Both facts matter.
The first is a drop in blood pressure, a slowed pulse and fainting [1]. The second is QT prolongation, a change in the heart’s electrical timing [1]. The third is increased central nervous system depression when it is taken with other medications that depress the central nervous system [1]. The fourth is an increased risk of opioid overdose after someone stops opioids, which has its own section below [1]. The fifth is a risk of symptoms on stopping the medication itself, which is why the label tells patients not to stop it without consulting their prescriber [1].
The common effects follow from the first warning. The label reports that the most common adverse reactions, at an incidence of at least 10 percent and notably more frequent than placebo, are orthostatic hypotension, bradycardia, hypotension, dizziness, somnolence, sedation and dry mouth [1]. In everyday words: light-headedness on standing, a slow pulse, low blood pressure, dizziness, drowsiness and a dry mouth.
Three interactions are named. Methadone and lofexidine both prolong the QT interval, and the label recommends electrocardiogram monitoring when they are used together [1]. Taking it with oral naltrexone may reduce how well the naltrexone works [1]. And certain medications that slow its breakdown in the liver can raise its levels, so the label asks for monitoring [1]. Our pages on methadone and buprenorphine cover those medications in their own right.
Two more entries belong in any honest summary. The safety of the medication in pregnant women has not been established [1]. And an overdose of it may show up as low blood pressure, a slow pulse and sedation [1].
If someone is having a seizure, is unresponsive or has trouble breathing, call 911. For a mental-health crisis call or text 988.
Where supervised withdrawal care happens in Washington
The Recovery Village Ridgefield is our campus in Ridgefield, Washington. Its own Levels of Care list publishes medical detox, inpatient treatment, a partial hospitalization program, intensive outpatient programming, dual diagnosis treatment and medication-assisted treatment. Which medications any individual is offered is decided by the clinician who admits them, and admissions will confirm what the campus can offer on the call.
See treatment options in Washington
Verify your insurance
The Recovery Village Ridgefield is part of our family of treatment centers. See the Recovery Village Ridgefield campus.
Lofexidine and clonidine: the same idea, different status
People often meet these two medications in the same conversation, and the difference is regulatory rather than mysterious.
Clonidine was first approved for high blood pressure, and it has been used in opioid withdrawal management since 1978 [3]. Federal guidance is careful to say it is not approved for that use, and is widely used off label for it [3].
Lofexidine is approved for it. Two randomized, double-blind, placebo-controlled trials supported its efficacy [1], and the indication on its label names opioid withdrawal directly [1].
That is the whole of the difference this page will assert. Which of them suits a particular person is a clinical decision that depends on their heart, their other medications and their history, and neither this page nor any page can make it. Our overview of medical detox covers the setting where that decision gets made.
It is not a treatment for opioid use disorder
This is the distinction the page exists for, and it is not a technicality.
The Food and Drug Administration has approved three medications for treating opioid use disorder: buprenorphine, methadone and naltrexone [2]. Lofexidine is not among them. It addresses a week; those three address a condition.
The label does not leave this to inference. It instructs that the medication be used in conjunction with a comprehensive management program for the treatment of opioid use disorder, and that patients and caregivers be informed of the increased risk of overdose [1].
So the right question after a course of it is not “did it work” but “what happens next”. Our pages on opioid addiction treatment and opioid replacement therapy set out what a longer plan looks like.
Federal guidance makes the same point about withdrawal management generally. It calls it a medical intervention that brings a person safely through acute withdrawal, and says plainly that detoxification is not substance use treatment and rehabilitation [5]. Most people need long-term treatment after detox [4].
The overdose risk the label warns about
This is the most important paragraph on the page.
The label states it directly. Patients who complete opioid discontinuation are at an increased risk of fatal overdose should they resume opioid use [1]. That warning sits in the same section as the instruction to inform patients and caregivers of the risk [1].
Federal drug information explains the mechanism in one sentence a reader can check. Most opioid overdose deaths occur in people who have just detoxed, because withdrawal reduces tolerance, so someone who has just been through it can overdose on a much smaller amount than they used to take [4].
Put plainly: the amount that was survivable a month ago may not be survivable next week. That is not a reason to avoid withdrawal management. It is a reason to have naloxone in the house and a plan for what follows, and to tell the people nearby what to watch for.
If someone is having a seizure, is unresponsive or has trouble breathing, call 911. For a mental-health crisis call or text 988.
Where it fits in an admission
One medication is a small part of what an admission decides.
Federal guidance describes withdrawal management in three parts: evaluation, stabilization, and fostering the person’s entry into treatment [5]. A medication like this one belongs to the second part. The first part is what works out whether it is appropriate at all, given someone’s heart, their other prescriptions and what else they have been using.
Federal guidance also notes that, unlike alcohol and sedative withdrawal, uncomplicated opioid withdrawal is not life-threatening [3]. That is not the same as saying a person should go through it alone, and the overdose risk above is exactly why.
Our explainers on levels of care, inpatient rehab and outpatient rehab set out the settings this happens in. Our pages on insurance coverage for rehab and what treatment costs explain the terms before a benefits call, how admission works sets out the steps, and our treatment centers lists the campuses we run.
Frequently Asked Questions
What is Lucemyra used for? Its approved use is the mitigation of opioid withdrawal symptoms, to help adults stop opioids abruptly. That is a deliberately narrow claim. The label adds that the medication may mitigate, but not completely prevent, the symptoms of opioid withdrawal. It is used alongside a comprehensive management program for the treatment of opioid use disorder rather than instead of one.
Is Lucemyra an opioid? No. Lofexidine is a central alpha-2 adrenergic agonist: it binds to receptors on adrenergic neurons and reduces the release of norepinephrine. It does not act at the opioid receptor. Federal guidance makes the same point about clonidine, an older medication in the same family, noting that withdrawal management with it happens without opioids.
What are the main side effects of Lucemyra? The label reports that the most common adverse reactions, at an incidence of at least 10 percent and notably more frequent than placebo, are orthostatic hypotension, bradycardia, hypotension, dizziness, somnolence, sedation and dry mouth. Its warnings cover low blood pressure, slowed pulse and fainting, QT prolongation, and increased central nervous system depression with other depressant medications.
Does Lucemyra treat opioid addiction? No. The FDA has approved three medications for treating opioid use disorder: buprenorphine, methadone and naltrexone. Lofexidine is not one of them; its approved use is the withdrawal period. Its own label says to use it alongside a comprehensive management program for opioid use disorder, and to inform patients and caregivers of the increased risk of overdose.
How is Lucemyra different from clonidine? Mainly in approval status. Clonidine was first approved for high blood pressure and has been used in opioid withdrawal management since 1978, and federal guidance notes it is not approved for that use and is widely used off label. Lofexidine is approved for it, supported by two randomized, double-blind, placebo-controlled trials. Which suits a person is a clinical decision.
Sources
- DailyMed. (2026). LUCEMYRA (lofexidine hydrochloride) tablet, film coated — prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0a848cc2-4dda-40d9-8b01-d789fe8981ed
- U.S. Food and Drug Administration. (2024). Information about Medications for Opioid Use Disorder (MOUD). FDA. https://www.fda.gov/drugs/information-drug-class/information-about-medications-opioid-use-disorder-moud
- Center for Substance Abuse Treatment. (2006). Detoxification and Substance Abuse Treatment — Chapter 4, Physical Detoxification Services for Withdrawal From Specific Substances. Treatment Improvement Protocol (TIP) Series No. 45, SAMHSA, via NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK64116/
- MedlinePlus. Opiate and opioid withdrawal. Medical Encyclopedia, U.S. National Library of Medicine, National Institutes of Health. https://medlineplus.gov/ency/article/000949.htm
- Center for Substance Abuse Treatment. (2006). Detoxification and Substance Abuse Treatment — Chapter 1, Overview, Essential Concepts, and Definitions in Detoxification. Treatment Improvement Protocol (TIP) Series No. 45, SAMHSA, via NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK64119/
This page is for general information and is not medical advice. Only a licensed clinician who knows your history can tell you what is right for you. If you or someone you know is in immediate danger, call 911. For free, confidential support 24/7, call or text 988.
Author
Chief Medical Officer,
The Recovery Village
